Interleukin-18 mediates interleukin-1-induced cardiac dysfunction

Effects of Interleukin-1 Blockade With Anakinra on Adverse Cardiac Remodeling and Heart Failure After Acute Myocardial Infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) Pilot Study]

(2013) Antonio Abbate et al.   AMERICAN JOURNAL OF CARDIOLOGY

Targeting Interleukin-1 in Heart Disease

(2013) Benjamin W. Van Tassell et al.   CIRCULATION

Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events

(2012) Antonio Abbate et al.   BIODRUGS

Inflammatory Cytokines in Heart Failure: Mediators and Markers

(2012) Lars Gullestad et al.   CARDIOLOGY

Recombinant Human Interleukin-1 Receptor Antagonist Provides Cardioprotection During Myocardial Ischemia Reperfusion in the Mouse

(2012) Stefano Toldo et al.   CARDIOVASCULAR DRUGS AND THERAPY

Heart Disease and Stroke Statistics—2013 Update

(2012) Alan S. Go et al.   CIRCULATION

Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse

(2012) Stefano Toldo et al.   EXPERIMENTAL PHYSIOLOGY

The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β

(2012) Nathan A. Bracey et al.   EXPERIMENTAL PHYSIOLOGY

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

(2012) Charles A. Dinarello et al.   NATURE REVIEWS DRUG DISCOVERY

Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure

(2012) Benjamin W. Van Tassell et al.   PLoS One

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

(2011) Paul M Ridker et al.   AMERICAN HEART JOURNAL

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

(2011) C. A. Dinarello   BLOOD

Right Ventricular Dysfunction following Acute Myocardial Infarction in the Absence of Pulmonary Hypertension in the Mouse

(2011) Stefano Toldo et al.   PLoS One

Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)

(2010) Antonio Abbate et al.   AMERICAN JOURNAL OF CARDIOLOGY

Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse

(2010) Antonio Abbate et al.   EUROPEAN JOURNAL OF HEART FAILURE

Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity

(2010) Jinzhou Zhu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Increased Cytokine Production in Interleukin-18 Receptor α-deficient Cells Is Associated with Dysregulation of Suppressors of Cytokine Signaling

(2009) Claudia A. Nold-Petry et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Neutralization of Interleukin-18 Ameliorates Ischemia/Reperfusion-induced Myocardial Injury

(2009) Kaliyamurthi Venkatachalam et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The effect of daily administration of IL-18 on cardiac structure and function

(2009) A Platis et al.   PERFUSION-UK

Interleukin-1 Receptor Type I Signaling Critically Regulates Infarct Healing and Cardiac Remodeling

(2008) Marcin Bujak et al.   AMERICAN JOURNAL OF PATHOLOGY

Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction

(2008) Antonio Abbate et al.   CIRCULATION

Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review

(2008) José Paulo Araújo et al.   JOURNAL OF CARDIAC FAILURE